

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance programme

STA Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | |
|------------------------------------------------------------------------------------------------------------------------------------|
| 1. Have any potential equality issues been identified during the scoping process been addressed by the committee, and, if so, how? |
|------------------------------------------------------------------------------------------------------------------------------------|

No equality issues were raised during the scoping process.

- | |
|---------------------------------------------------------------------------------------------------------------------|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---------------------------------------------------------------------------------------------------------------------|

People with neurodegenerative conditions or mental health issues with residual excessive daytime sleepiness could be discriminated against if the recommendations restricted pitolisant for use with continuous positive airway pressure only.

- | |
|----------------------------------------------------------------------------------------------------------------------------------|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|----------------------------------------------------------------------------------------------------------------------------------|

No other issues identified.

- | |
|--------------------------------------------------------------------------------------------------------------------------------------------|
| 4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other |
|--------------------------------------------------------------------------------------------------------------------------------------------|

groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No, pitolisant hydrochloride is not recommended. The appraisal committee will take this issue into account if pitolisant hydrochloride is recommended in the future.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No, pitolisant hydrochloride is not recommended. The appraisal committee will take this issue into account if pitolisant hydrochloride is recommended in the future.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
Not applicable
7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Yes, see section 3.19 of the ACD

Approved by Associate Director (name): Jasdeep Hayre

Date: 30 April 2021

Final appraisal determination

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No additional issues were raised.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No, the recommendation has not changed.

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No, the recommendation has not changed.

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No, the recommendation has not changed.

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, section 3.16 of the FAD.

Approved by Associate Director (name): Jasdeep Hayre

Date: 19 January 2022